Upregulation of iron regulatory hormone hepcidin by interferon α

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 2, 2014, Pages 387-394

  Ichiki, Kazuhiko ^a   Ikuta, Katsuya ^a   Addo, Lynda ^a   Tanaka, Hiroki ^b   Sasaki, Yusuke ^d   Shimonaka, Yasushi ^d   Sasaki, Katsunori ^b   Ito, Satoshi ^a   Shindo, Motohiro ^a   Ohtake, Takaaki ^a   Fujiya, Mikihiro ^a   Torimoto, Yoshihiro ^c   Kohgo, Yutaka ^a  

^a Division of Gastroenterology and Hematology/Oncology   (Japan)

^b Department of Gastrointestinal Immunology and Regenerative Medicine ^*  (Japan)

^c ASAHIKAWA MEDICAL COLLEGE   (Japan)

^d CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Hepcidin; Interferon; Iron

Indexed keywords

FERROPORTIN; HEPCIDIN; IRON; MESSENGER RNA; RECOMBINANT ALPHA INTERFERON; STAT3 PROTEIN; ALPHA INTERFERON; CATION TRANSPORT PROTEIN; INTERFERON; METAL TRANSPORTING PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW; CONTROLLED STUDY; DRUG EFFECT; DUODENUM; GENE EXPRESSION; GENE TARGETING; HEPATOMA CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; IN VIVO STUDY; IRON METABOLISM; LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY; LIVER; LIVER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SERUM; SPLEEN; TANDEM MASS SPECTROMETRY; WESTERN BLOTTING; ANIMAL; BLOOD; C57BL MOUSE; CELL CULTURE; GENETICS; IRON OVERLOAD; LIQUID CHROMATOGRAPHY; LIVER CELL CARCINOMA; METABOLISM; POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; UPREGULATION;

HEPCIDIN; INTERFERON; IRON;

ANIMALS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CATION TRANSPORT PROTEINS; CELLS, CULTURED; CHROMATOGRAPHY, LIQUID; DUODENUM; GENE EXPRESSION; HEPATOCYTES; HEPCIDINS; INTERFERON-ALPHA; IRON; IRON OVERLOAD; LIVER; MICE; MICE, INBRED C57BL; POLYMERASE CHAIN REACTION; RNA, MESSENGER; TANDEM MASS SPECTROMETRY; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 84907284853     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12348     Document Type: Article

References (28)

1. Andrews NC. Disorders of iron metabolism. N. Engl. J. Med. 1999; 341: 1986-1995.
2. Hentze MW, Muckenthaler MU, Andrews NC. Balancing acts: molecular control of mammalian iron metabolism. Cell 2004; 117: 285-297.
3. Andrews NC. Forging a field: the golden age of iron biology. Blood 2008; 112: 219-230.
4. Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to tango: regulation of Mammalian iron metabolism. Cell 2010; 142: 24-38.
5. Ganz T. Hepcidin and iron regulation, 10 years later. Blood 2011; 117: 4425-4433.
6. Ganz T, Nemeth E. Iron imports. IV. Hepcidin and regulation of body iron metabolism. Am. J. Physiol. Gastrointest. Liver Physiol. 2006; 290: G199-203.
7. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J. Biol. Chem. 2001; 276: 7806-7810.
8. Krause A, Neitz S, Mägert HJ etal. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett. 2000; 480: 147-150.
9. Nemeth E, Tuttle MS, Powelson J etal. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004; 306: 2090-2093.
10. Pietrangelo A. Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. Gastroenterology 2010; 139: 393-408. 408.e1-2.
11. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003; 101: 2461-2463.
12. Nemeth E, Rivera S, Gabayan V etal. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Invest. 2004; 113: 1271-1276.
13. Inamura J, Ikuta K, Jimbo J etal. Upregulation of hepcidin by interleukin-1beta in human hepatoma cell lines. Hepatol. Res. 2005; 33: 198-205.
14. Kohgo Y, Ikuta K, Ohtake T, Torimoto Y, Kato J. Body iron metabolism and pathophysiology of iron overload. Int. J. Hematol. 2008; 88: 7-15.
15. Kohgo Y, Ikuta K, Ohtake T, Torimoto Y, Kato J. Iron overload and cofactors with special reference to alcohol, hepatitis C virus infection and steatosis/insulin resistance. World J. Gastroenterol. 2007; 13: 4699-4706.
16. Nagashima M, Kudo M, Chung H etal. Regulatory failure of serum prohepcidin levels in patients with hepatitis C. Hepatol. Res. 2006; 36: 288-293.
17. Yada N, Kudo M, Chung H etal. PEG-IFNalpha/RBV combination therapy for chronic hepatitis C patients increases serum ferritin level while it improves sustained viral response rate. Intervirology 2010; 53: 60-65.
18. Kato J, Miyanishi K, Kobune M etal. Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. J. Gastroenterol. 2007; 42: 830-836.
19. Fujita N, Sugimoto R, Takeo M etal. Hepcidin expression in the liver: relatively low level in patients with chronic hepatitis C. Mol. Med. 2007; 13: 97-104.
20. Fujita N, Sugimoto R, Motonishi S etal. Patients with chronic hepatitis C achieving a sustained virological response to peginterferon and ribavirin therapy recover from impaired hepcidin secretion. J. Hepatol. 2008; 49: 702-710.
21. Murao N, Ishigai M, Yasuno H, Shimonaka Y, Aso Y. Simple and sensitive quantification of bioactive peptides in biological matrices using liquid chromatography/selected reaction monitoring mass spectrometry coupled with trichloroacetic acid clean-up. Rapid Commun. Mass Spectrom. 2007; 21: 4033-4038.
22. Hosoki T, Ikuta K, Shimonaka Y etal. Heterogeneous expressions of hepcidin isoforms in hepatoma-derived cells detected using simultaneous LC-MS/MS. Proteomics Clin. Appl. 2009; 3: 1256-1264.
23. Radaeva S, Jaruga B, Hong F etal. Interferon-alpha activates multiple STAT signals and down-regulates c-Met in primary human hepatocytes. Gastroenterology 2002; 122: 1020-1034.
24. Testoni B, Schinzari V, Guerrieri F, Gerbal-Chaloin S, Blandino G, Levrero M. p53-paralog DNp73 oncogene is repressed by IFNα/STAT2 through the recruitment of the Ezh2 polycomb group transcriptional repressor. Oncogene 2011; 30: 2670-2678.
25. Terawaki S, Chikuma S, Shibayama S etal. IFN-α directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. J. Immunol. 2011; 186: 2772-2779.
26. Thibault DL, Graham KL, Lee LY, Balboni I, Hertzog PJ, Utz PJ. Type I interferon receptor controls B-cell expression of nucleic acid-sensing Toll-like receptors and autoantibody production in a murine model of lupus. Arthritis Res. Ther. 2009; 11: R112.
27. Ryan JD, Altamura S, Devitt E etal. Pegylated interferon-α induced hypoferremia is associated with the immediate response to treatment in hepatitis C. Hepatology 2012; 56: 492-500.
28. Ikuta K, Zak O, Aisen P. Recycling, degradation and sensitivity to the synergistic anion of transferrin in the receptor-independent route of iron uptake by human hepatoma (HuH-7) cells. Int. J. Biochem. Cell Biol. 2004; 36: 340-352.